Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adjuvant for transcutaneous immunization

a technology of adjuvant and immunization, applied in the field of adjuvant, can solve the problem of not being expected to achieve immunization

Inactive Publication Date: 2006-11-30
UNITED STATES OF AMERICA
View PDF99 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a system for transcutaneous immunization that can induce an immune response in an animal or human by applying a formulation containing antigen and adjuvant to the skin. The antigen can be a pathogen, tumor antigen, or autoantigen. The system can protect against disease, treat existing disease, or reduce the severity and duration of disease. The formulation can include additional antigens, and the antigen can be at least partially purified or provided in the form of a live virus, attenuated live virus, or inactivated virus. The inclusion of an adjuvant can potentiate or modulate the immune response. The method can be used therapeutically, preventively, or to reduce the severity and duration of disease. The formulation can be applied over multiple draining lymph node fields using multiple patches. The products and methods can be used to treat existing disease, protect against disease, or reduce the severity and duration of disease.

Problems solved by technology

Therefore, the reference would teach away from using a molecule like cholera toxin (which is 85,000 daltons) because such molecules would not be expected to penetrate the skin and, therefore, would not be expected to achieve immunization.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant for transcutaneous immunization
  • Adjuvant for transcutaneous immunization

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0115] BALB / c mice at 6 to 8 weeks of age were immunized transcutaneously as described above for “Immunization Procedure”, in groups of five mice. The mice were immunized using 100 μl of immunization solution which was prepared as follows: liposomes prepared as described above for “Liposome Preparation” were mixed with saline to form the liposomes. The pre-formed liposomes were then diluted in either saline (liposome alone group) or with CT in saline to yield an immunizing solution containing liposomes at 10-150 mM phospholipid with 100 μg of CT per 100 μl of immunizing solution. CT was mixed in saline to make an immunizing solution containing 100 μg of CT per 100 μg of solution for the group receiving CT alone. Solutions were vortexed for 10 seconds prior to immunization.

[0116] The mice were immunized transcutaneously at 0 and 3 weeks. Antibody levels were determined using ELISA as described above for “ELISA IgG(H+L)” 3 weeks after the boosting immunization, and compared against p...

example 2

[0117] BALB / c mice at 6 to 8 weeks of age were immunized transcutaneously as described above for “Immunization Procedure”, in groups of five mice. The mice were immunized at 0 and 3 weeks using 100 μl of immunization solution prepared as follows: BSA was mixed in saline to make an immunizing solution containing 200 μg of BSA per 100 μl of saline for the group receiving BSA alone; BSA and CT were mixed in saline to make an immunizing solution containing 200 μg of BSA and 100 μg of CT per 100 μl of saline for the group receiving BSA and CT. Where liposomes were used, the liposomes were prepared as described above for “Liposome Preparation”, and were first mixed with saline to form the liposomes. They were then diluted in BSA or BSA and CT in saline to yield an immunizing solution containing liposomes at 50 mM phospholipid with 200 μg of BSA per 100 μl of immunizing solution, or 200 μg BSA+100 μg CT per 100 μl of immunizing solution. Solutions were vortexed for 10 seconds prior to immu...

example 3

[0119] BALB / c mice at 6 to 8 weeks of age were immunized transcutaneously as described above for “Immunization Procedure”, in groups of five mice. The mice were immunized at 0 and 3 weeks using 100 μl of immunization solution prepared as follows: LT was mixed in saline to make an immunizing solution containing 100 μg of LT per 100 μl of saline for the group receiving LT alone. Where liposomes were used the liposomes prepared as described above for “Liposome Preparation”, and were first mixed with saline to form the liposomes. The pre-formed liposomes were then diluted in LT in saline to yield an immunizing solution containing liposomes at 50 mM phospholipid with 100 μg of LT per 100 μl of immunizing solution. Solutions were vortexed for 10 seconds prior to immunization.

[0120] The anti-LT antibodies were determined using ELISA as described above for “ELISA IgG(H+L)” 3 weeks after the second immunization. The results are shown in Table 3. LT was clearly immunogenic both with and with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This is a continuation in-part of U.S. application Ser. No. 08 / 749,164 filed Nov. 14, 1996.GOVERNMENT RIGHTS [0002] The U.S. government may retain certain rights in this invention.BACKGROUND [0003] The invention relates to transcutaneous immunization, and adjuvants useful therein, to induce an antigen-specific immune response. [0004] Transcutaneous immunization requires both passage of an antigen through the outer barriers of the skin, which are normally impervious to such passage, and an immune response to the antigen. We showed in U.S. application Ser. No. 08 / 749,164 that using cholera toxin as an antigen elicits a strong antibody response that is highly reproducible; the antigen could be applied in a saline solution to the skin, with or without liposomes. In the present application, we show transcutaneous immunization using adjuvants such as, for example, bacterial exotoxins, their subunits, and related toxins. [0005] There is a repo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K39/00A61K9/127A01N37/18A61F13/00A61K9/00A61K9/06A61K9/08A61K9/107A61K9/52A61K9/56A61K9/70A61K35/14A61K35/39A61K39/015A61K39/05A61K39/08A61K39/10A61K39/102A61K39/104A61K39/106A61K39/39A61P37/00A61P37/04
CPCA61K9/06A61K9/08A61K9/107A61K9/127A61K9/7023A61K39/39B82Y5/00A61K2039/54A61K2039/55511A61K2039/55527A61K2039/55544A61K2039/55555A61K2039/55566A61K2039/53A61P37/00A61P37/04A61K39/00
Inventor GLENN, GREGORY M.ALVING, CARL R.
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com